focus -WSS

focus

author：leisure time 2025-09-27 16:49:03 - browse：37

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： UCB departs biotech trade group BIO

hotspot

WSS

How AI helped researchers track recovery from depression

CommonSpirit Health keeps growing, even as it loses money

Experts study whether long Covid risk adds up with each reinfection

Experts study whether long Covid risk adds up with each reinfection

Burning questions for the 2024 JPM Healthcare Conference

JPM: CVS says Medicare Advantage patients are impacting profits

focus

focus

hotspot

Continuity nursing helped my family in our darkest PICU moments

Medical student insurance fails on mental health care coverage

Hollywood unions extend contract negotiations for actors

Why are Kaiser Permanente staff considering a strike?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

DIEP, the 'gold standard' of breast reconstruction, is under threat

Feng Zhang CRISPR delivery startup lays off quarter of staff

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Drug for rare kidney disease narrowly misses mark in clinical trial

knowledge

How AI helped researchers track recovery from depression

Changes to biosimilar regulatory framework must prioritize patients

Feng Zhang CRISPR delivery startup lays off quarter of staff

CDC advisers recommend seasonal use of Pfizer RSV shot

STAT Virtual Event: Putting AI to the Test

Videos point to link between seizures and unexplained toddler deaths

explore

hotspot

focus

entertainment